Komori
Share Issuance and Disposal190AChordia Therapeutics Inc.Pharmaceuticals

Notice Concerning the Monthly Exercise Status of the 12th Stock Acquisition Rights (with Exercise Price Adjustment Clause)

In October 2026, 12,000 Series 12 Stock Acquisition Rights were exercised and 1.2 million new shares were delivered. The number of rights remaining unexercised at month-end was 171,220.

Worth reading
66In focus
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1200000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Report on the exercise status of Series 12 Stock Acquisition Rights with an exercise price adjustment clause

発行・処分する株式数

Number of shares delivered during the month: 1,200,000 shares (1,200,000 new shares, no transfer of treasury shares)

Terms of the stock acquisition rights
Exercise price
With an exercise price adjustment clause. The exercise price during the target month ranged from ¥45.0 to ¥62.1 per day. The lower limit of the adjustment was Not disclosed.
Number of Stock Acquisition Rights
Total issued: Not disclosed; unexercised at the end of the month preceding the target month: 183,220; unexercised at the end of the target month: 171,220
Procedures under the Corporate Code of Conduct
Describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange Rules on Listing and the Japan Securities Dealers Association Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing
Issued 9 September 2026: Series 12 Stock Acquisition Rights (with an exercise price adjustment clause), amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalReport on the exercise status of Series 12 Stock Acquisition Rights with an exercise price adjustment clause
Number of shares to be issued or disposed ofNumber of shares delivered during the month: 1,200,000 shares (1,200,000 new shares, no transfer of treasury shares)
Total number of issued shares77,358,400 shares (as of the end of the month preceding the target month, including 0 treasury shares) → Not disclosed
Exercise priceWith an exercise price adjustment clause. The exercise price during the target month ranged from ¥45.0 to ¥62.1 per day. The lower limit of the adjustment was Not disclosed.
Number of Stock Acquisition RightsTotal issued: Not disclosed; unexercised at the end of the month preceding the target month: 183,220; unexercised at the end of the target month: 171,220
Procedures under the Corporate Code of ConductDescribes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange Rules on Listing and the Japan Securities Dealers Association Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financingIssued 9 September 2026: Series 12 Stock Acquisition Rights (with an exercise price adjustment clause), amount Not disclosed
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status. No individual reasons for exercise have been stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Monthly Exercise Status of the 12th Stock Acquisition Rights (with Exercise Price Adjustment Clause) | Chordia Therapeutics Inc. (190A) timely disclosure | Komori